NINDS Competing Renewal Awards of SBIR Phase II (Phase IIB) Grants (SBIR R44) | Apply Online

Frequently Asked Questions (FAQs): NINDS Competing Renewal Awards of SBIR Phase II (Phase IIB) Grants (SBIR R44) - PAR-12-077

What is PAR-12-077?

PAR-12-077 is an NIH discretionary grant opportunity from the National Institute of Neurological Disorders and Stroke (NINDS) for Competing Renewal Awards of SBIR Phase II (often referred to as Phase IIB) under the SBIR R44 mechanism. It is intended as follow-on support for small businesses that have already completed an NIH SBIR Phase II project and need additional funding to advance a technology into a later, more expensive, and regulatory-focused stage of development.

What is the main purpose of this funding opportunity?

The central purpose is to accelerate the transition from promising research and development into commercial product development. In practice, the FOA is designed to help move technologies from a successful Phase II outcome toward true commercial readiness, especially when the remaining steps involve regulatory-driven development work.

What types of projects does this FOA target?

This FOA targets projects in the neurosciences and neurological disorders space aligned with NINDS priorities (CFDA 93.853). It is particularly focused on projects where the remaining work to reach market includes late-stage development tasks tied to approval or clearance by a federal regulatory agency.

What kinds of activities are considered a good fit for Phase IIB under this FOA?

The FOA emphasizes late-stage, regulatory-relevant development activities such as preparing for federal regulatory interactions (for example, FDA interactions), generating data needed for regulatory submissions, and conducting studies required to support safety or performance claims. These activities commonly fall between a successful Phase II prototype and full commercial readiness.

Who is eligible to apply?

Eligibility is limited to small business concerns, consistent with SBIR program rules. The award mechanism is an SBIR R44 grant and the small business is expected to lead the project.

Do applicants need to have completed an NIH SBIR Phase II project to apply?

Yes. This opportunity is specifically described as a competing renewal/follow-on for small businesses that have already completed an NIH SBIR Phase II project and now need additional support for the next stage.

What is meant by "Competing Renewal" in this context?

Based on the description provided, "competing renewal" refers to additional, follow-on SBIR support beyond Phase II (often called Phase IIB) that is competed for, rather than automatically extended, and is aimed at advancing the technology into late-stage development milestones.

What is the SBIR R44 mechanism and why is it used here?

The FOA uses the SBIR R44 grant mechanism. The description notes that R44 is often associated with SBIR projects that may involve partnerships (including with research institutions) while remaining led by the small business.

Is a Commercialization Plan required?

Yes. Applicants are required to submit a Commercialization Plan as is standard for SBIR Phase II-type applications under SF424 instructions. In this FOA, the commercialization plan is especially important because it must clearly describe how the company will finance and execute commercialization.

What needs to be addressed in the Commercialization Plan for this FOA?

The plan should spell out how commercialization will be financed and executed, including the role of outside investors and/or strategic partners. The FOA places strong emphasis on market-facing partnerships and credible third-party support as evidence of commercial viability.

Does this program require cost sharing or a formal match?

No formal cost sharing or matching requirement is stated. However, the practical design operates like a leverage model because NINDS expects substantial independent third-party support alongside the federal funds.

How important is third-party funding or independent support in this FOA?

It is a central expectation. NINDS is explicit that it wants companies to attract independent, third-party support as a signal that the product has commercial credibility beyond NIH funding. The FOA expects the level of secured or anticipated third-party support during the Phase IIB period to be at least equal to, and ideally exceed, the amount of NINDS funding requested.

Does third-party support have to already be secured at the time of application?

The description indicates the FOA expects third-party funding to be secured or anticipated during the Phase IIB project period, and that this support should be documented and aligned with the project timeline. The FOA emphasizes credible investor or strategic partner interest that can be demonstrated.

What does NIH mean by "de-risk" in this program?

In the context provided, NIH aims to help de-risk and advance the project through regulatory and product-development milestones, but not to serve as the only or primary source of capital at this stage. The program is intended to bridge the gap while the company brings in meaningful outside funding and partnerships.

What kinds of applicants is this opportunity particularly relevant for?

This opportunity is described as particularly relevant for small businesses that (1) have strong Phase II results, (2) have a clear regulatory pathway requiring additional studies or development work, and (3) have credible investor or strategic partner interest that can be documented and matched to the project timeline.

Which federal agency’s regulatory expectations are referenced?

The FOA references work tied to approval or clearance by a federal regulatory agency and gives the FDA as an example, including preparing for FDA interactions and generating data needed for regulatory submissions.

Which NIH institute sponsors this FOA?

The sponsoring agency is the National Institutes of Health (NIH), and the FOA is specifically tied to the National Institute of Neurological Disorders and Stroke (NINDS) within NIH.

What is the CFDA number associated with this opportunity?

The opportunity is associated with CFDA 93.853.

When was this opportunity posted and when did it close?

The opportunity was posted and created on January 11, 2012. It had an original and final closing date of September 7, 2013, and an archive date of October 8, 2013.

Where was the full announcement hosted?

The full announcement was hosted on the NIH grants policy/guide website (as referenced in the provided description).

Who is listed as a support contact for access or linking issues?

The description references support contacts including NIH Office of Extramural Research (OER) webmaster emails for access or linking issues.

Is this FOA best viewed as early research funding or late-stage bridge funding?

Based on the description, it is best understood as late-stage SBIR bridge funding for NINDS-relevant technologies. It is aimed at companies that have already shown feasibility in Phase II and now need a final push through regulatory and product-development milestones while demonstrating meaningful outside capital or strategic support.